SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Formerly About Advanced Micro Devices
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Eric who wrote (1428377)12/12/2023 2:15:00 PM
From: Broken_Clock1 Recommendation

Recommended By
longz

  Read Replies (1) of 1575947
 
You did not specifically answer my post. But, since you spewed out the first thing you found, read on:

(You should read what you post)

Although these results are promising, the duration of antibody response is a complex phenomenon which will vary highly from antigen to antigen. Additionally, evaluating the duration of immune response by MRNA vaccines requires longer-term data for a comprehensive understanding.
--

Anti-PEG antibodies are reported in 40% of the population, which can accelerate and heighten the risk of allergic reactions and impede vaccine efficacy [ 160]. The CDC recommends that mRNA vaccines should not be given to people with a history of allergic response to the Pfizer–BioNTech or Moderna vaccines. Since some components of mRNA vaccine formulations can cause allergic reactions in a fraction of the population, the formulation components should be re-engineered for enhanced safety profiles.

---

mRNA vaccines might be just the solution for boosting geriatric immunity.

---

Thanks for proving my point that there are no long term, peerr reviewed studies proving the long term safety of mRNA "vaccines". Good to know Big Pharma has lab rats like you to experiment on.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News